← Back to patent-cliff list
Valganciclovir
Tier C — Watch / tradeValganciclovir
Skiron Biosciences
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Virus DNA polymerase
Indications (approved)：巨细胞病毒感染, Kidney disease, Kidney transplant rejection, 葡萄膜炎
Regional status
US
Phase III
2025-07-22
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Valganciclovir?
Approved indications include: 巨细胞病毒感染, Kidney disease, Kidney transplant rejection, 葡萄膜炎.
When does the Valganciclovir patent expire?
No public expiry year is available for Valganciclovir yet; this page updates once verified.
How do I get a quote for Valganciclovir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30